ORM-1023

N/A

Report date: 2024/11/22 09:35:07

Base Information

Drug NameORM-1023
Drug Alias NameORM-1023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A modulatorsCereblon modulators
TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3ACereblon
Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOrum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrum Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A